Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Non Operating Income (2021 - 2025)

Prime Medicine's Non Operating Income history spans 5 years, with the latest figure at $7.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 254.61% year-over-year to $7.1 million; the TTM value through Dec 2025 reached $11.0 million, up 26778.05%, while the annual FY2025 figure was $7.2 million, 17480.49% up from the prior year.
  • Non Operating Income reached $7.1 million in Q4 2025 per PRME's latest filing, up from $3.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.1 million in Q4 2025 to a low of -$8.4 million in Q3 2021.
  • Average Non Operating Income over 5 years is $113055.6, with a median of $370000.0 recorded in 2022.
  • Peak YoY movement for Non Operating Income: tumbled 395.32% in 2022, then skyrocketed 19309.09% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$1.5 million in 2021, then crashed by 395.32% to -$7.2 million in 2022, then skyrocketed by 133.32% to $2.4 million in 2023, then tumbled by 291.58% to -$4.6 million in 2024, then skyrocketed by 254.61% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Non Operating Income are $7.1 million (Q4 2025), $3.4 million (Q3 2025), and $18000.0 (Q2 2025).